Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (41-50 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|November 19, 2015
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysisMark J Bishton, Simon Hughes, Faith Richardson, et al.
Blood|January 14, 2021
Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cellsPaul J Collins, Christopher P Fox, Lindsay George, et al.
Frontiers in Immunology|November 19, 2019
Non-uniform <i>in vivo</i> Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative DiseaseDavid M Burns, Gordon B Ryan, Caroline M Harvey, et al.
Rheumatology (Oxford, England)|October 31, 2021
Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and AurumGeorgina Nakafero, Matthew J Grainge, Tim Card, et al.
British Journal of Haematology|November 24, 2018
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphomaChristopher P Fox, Elizabeth H Phillips, Jeffery Smith, et al.
BMC Cancer|September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphomaJulia Wendler, Christopher P Fox, Elke Valk, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
RMD Open|March 7, 2024
Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validationAbhishek Abhishek, Matthew Grainge, Tim Card, et al.
The Lancet. Haematology|July 5, 2021
Antibody responses after SARS-CoV-2 vaccination in patients with lymphomaSean H Lim, Nicola Campbell, Marina Johnson, et al.
British Journal of Haematology|May 19, 2025
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology GuidelineSridhar Chaganti, Christopher P Fox, Bernard D Maybury, et al.
Pageof 13

Showing results (41-50 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|November 19, 2015
Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysisMark J Bishton, Simon Hughes, Faith Richardson, et al.
Blood|January 14, 2021
Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cellsPaul J Collins, Christopher P Fox, Lindsay George, et al.
Frontiers in Immunology|November 19, 2019
Non-uniform <i>in vivo</i> Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative DiseaseDavid M Burns, Gordon B Ryan, Caroline M Harvey, et al.
Rheumatology (Oxford, England)|October 31, 2021
Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and AurumGeorgina Nakafero, Matthew J Grainge, Tim Card, et al.
British Journal of Haematology|November 24, 2018
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphomaChristopher P Fox, Elizabeth H Phillips, Jeffery Smith, et al.
BMC Cancer|September 10, 2022
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphomaJulia Wendler, Christopher P Fox, Elke Valk, et al.
British Journal of Haematology|January 22, 2024
The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology GuidelineChristopher P Fox, Sridhar Chaganti, Graham McIlroy, et al.
RMD Open|March 7, 2024
Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validationAbhishek Abhishek, Matthew Grainge, Tim Card, et al.
The Lancet. Haematology|July 5, 2021
Antibody responses after SARS-CoV-2 vaccination in patients with lymphomaSean H Lim, Nicola Campbell, Marina Johnson, et al.
British Journal of Haematology|May 19, 2025
Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology GuidelineSridhar Chaganti, Christopher P Fox, Bernard D Maybury, et al.
Pageof 13